US 12,441,810 B2
Protein S antibodies, methods of making and uses thereof
Sandip Panicker, South San Francisco, CA (US); Adam David Rosenthal, South San Francisco, CA (US); Tony Sang Young Byun, South San Francisco, CA (US); and Quehuong Thi Dong, South San Francisco, CA (US)
Assigned to Vega Therapeutics, Inc., South San Francisco, CA (US)
Appl. No. 17/923,503
Filed by Vega Therapeutics, Inc., South San Francisco, CA (US)
PCT Filed May 5, 2021, PCT No. PCT/US2021/030900
§ 371(c)(1), (2) Date Nov. 4, 2022,
PCT Pub. No. WO2021/226243, PCT Pub. Date Nov. 11, 2021.
Claims priority of provisional application 63/169,755, filed on Apr. 1, 2021.
Claims priority of provisional application 63/020,505, filed on May 5, 2020.
Prior Publication US 2023/0083243 A1, Mar. 16, 2023
Int. Cl. C07K 16/36 (2006.01); A61K 47/68 (2017.01); A61P 7/04 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/36 (2013.01) [A61K 47/6843 (2017.08); A61P 7/04 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/32 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. An antibody that binds Protein S, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprise a combination of six complementarity determining regions (CDRs), whose amino acid sequences comprise a CDR-L1 comprising the sequence of SEQ ID NO: 1, a CDR-L2 comprising an amino acid sequence of QDT, a CDR-L3 comprising the sequence of SEQ ID NO: 21, a CDR-H1 comprising the sequence of SEQ ID NO: 33, a CDR-H2 comprising the sequence of SEQ ID NO: 45, and a CDR-H3 comprising the sequence of SEQ ID NO: 57.